Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:VRP
- CUSIP: N/A
- Web: www.veronapharma.com/
- Market Cap: £124.36 million
- Outstanding Shares: 88,516,000
- 50 Day Moving Avg: GBX 126.20
- 200 Day Moving Avg: GBX 130.85
- 52 Week Range: GBX 100 - GBX 210
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 1.05 per share
- Price / Book: 1.34
- Average Volume: 53,148 shs.
Frequently Asked Questions for Verona Pharma Plc (LON:VRP)
What is Verona Pharma Plc's stock symbol?
Verona Pharma Plc trades on the London Stock Exchange (LON) under the ticker symbol "VRP."
Where is Verona Pharma Plc's stock going? Where will Verona Pharma Plc's stock price be in 2017?
4 brokers have issued 1 year price objectives for Verona Pharma Plc's stock. Their forecasts range from GBX 22 to GBX 250. On average, they expect Verona Pharma Plc's stock price to reach GBX 80.75 in the next year. View Analyst Ratings for Verona Pharma Plc.
Who are some of Verona Pharma Plc's key competitors?
Some companies that are related to Verona Pharma Plc include DURECT Corporation (DRRX), Faron Pharmaceuticals Oy (FARN), Pieris Pharmaceuticals (PIRS), Chimerix (CMRX), ObsEva SA (OBSV), OVID THERAPEUTC (OVID), uniQure N.V. (QURE), Mast Therapeutics (SVRA), Foamix Pharmaceuticals (FOMX), MannKind Corporation (MNKD), OncoCyte Corp (OCX), Kindred Biosciences (KIN), Catalyst Pharmaceuticals (CPRX), Cascadian Therapeutics (CASC), Vital Therapies (VTL), Zymeworks (ZYME), Clearside Biomedical (CLSD) and Spring Bank Pharmaceuticals (SBPH).
Who are Verona Pharma Plc's key executives?
Verona Pharma Plc's management team includes the folowing people:
- Sven Jan-Anders Karlsson, Chief Executive Officer, Executive Director
- Kenneth B. Newman M.D., Chief Medical Officer
- Ben Harber, Company Secretary
- David Raymond Ebsworth Ph.D., Non-Executive Chairman of the Board
- Kenneth D. Cunningham M.D., Non-Executive Director
- Vikas Sinha CPA, Non-Executive Director
- Anders Ullman M.D., Ph.D., Non-Executive Director
How do I buy Verona Pharma Plc stock?
Shares of Verona Pharma Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Verona Pharma Plc's stock price today?
MarketBeat Community Rating for Verona Pharma Plc (LON VRP)MarketBeat's community ratings are surveys of what our community members think about Verona Pharma Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Verona Pharma Plc stock can currently be purchased for approximately GBX 140.50.
Consensus Ratings for Verona Pharma Plc (LON:VRP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 80.75|
Analysts' Ratings History for Verona Pharma Plc (LON:VRP)
(Data available from 9/21/2015 forward)
|6/27/2017||N+1 Singer||Reiterated Rating||corporate|
|6/9/2017||Jefferies Group LLC||Reiterated Rating||Buy||GBX 250|
|5/22/2017||Wedbush||Initiated Coverage||Outperform||GBX 25|
|5/22/2017||SunTrust Banks, Inc.||Initiated Coverage||Buy||GBX 26|
|5/22/2017||Stifel Nicolaus||Initiated Coverage||Buy||GBX 22|
Earnings History for Verona Pharma Plc (LON:VRP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Verona Pharma Plc (LON:VRP)
Current Year EPS Consensus Estimate: $-38.15 EPS
Dividend History for Verona Pharma Plc (LON:VRP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Verona Pharma Plc (LON:VRP)Insider Trades by Quarter for Verona Pharma Plc (LON:VRP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/27/2017||David Ebsworth||Insider||Buy||177,776||GBX 169||£300,441.44|
|4/26/2017||David Ebsworth||Insider||Buy||13,373||GBX 132||£17,652.36|
|3/1/2017||Sven Jan-Anders Karlsson||Insider||Buy||7,750||GBX 149||£11,547.50|
|2/28/2017||Sven Jan-Anders Karlsson||Insider||Buy||12,000||GBX 149||£17,880|
|8/9/2016||Jan-Anders Karlsson,Sven||Insider||Buy||600,000||GBX 3||£18,000|
|6/17/2015||David Ebsworth||Insider||Buy||250,000||GBX 4.70||£11,750|
|5/18/2015||David Ebsworth||Insider||Buy||300,000||GBX 3.50||£10,500|
|3/3/2015||David Ebsworth||Insider||Buy||450,000||GBX 2.43||£10,935|
|2/16/2015||Biresh Roy||Insider||Buy||500,000||GBX 2.30||£11,500|
|2/13/2015||Sven Jan-Anders Karlsson||Insider||Buy||1,025,909||GBX 2||£20,518.18|
|2/4/2015||David Ebsworth||Insider||Buy||700,000||GBX 1.54||£10,780|
|1/19/2015||Stuart Bottomly||Insider||Buy||1,000,000||GBX 1.50||£15,000|
|1/13/2015||David Ebsworth||Insider||Buy||803,107||GBX 1.35||£10,841.94|
Headline Trends for Verona Pharma Plc (LON:VRP)
Latest Headlines for Verona Pharma Plc (LON:VRP)
Verona Pharma Plc (VRP) Chart for Thursday, September, 21, 2017